Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), R. Kokko, Arja Jukkola‐Vuorinen(University of Oulu), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Outi Saarni(Turku University Hospital), Johan Ahlgren(Uppsala University), Vesa Kataja(Kuopio University Hospital), Riikka Huovinen(Turku University Hospital), Greger Nilsson(Turku University Hospital), Pirkko‐Liisa Kellokumpu‐Lehtinen, Kenneth Villman(Örebro University Hospital), Petri Bono(Helsinki University Hospital), Mika Leinonen, Leena Helle(Kotka Maritime Research Centre)
Cited by 24
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k